PURPOSE: Bronchoalveolar lavage (BAL) and (18)F-fluorodeoxyglucose ((18)F-FDG) PET can both demonstrate sarcoid activity. To assess whether metabolic activity imaged by (18)F-FDG PET represents signs of disease activity as reflected by BAL, (18)F-FDG PET patterns were compared with BAL cell profiles. METHODS: In this retrospective analysis, 77 newly diagnosed pulmonary sarcoidosis patients underwent BAL and (18)F-FDG PET. Based on (18)F-FDG PET, patients were diagnosed with exclusively mediastinal/hilar activity (group A) and activity in the lung parenchyma (group B). Per group, BAL lymphocytes (%), CD4/CD8 ratio, CD103(+)CD4(+)/CD4(+) ratio and neutrophils (%) were compared with the extent of metabolic activity expressed as the maximum standardized uptake value (SUV(max)). Additionally, SUV(max) and BAL parameters per radiographic stage were analysed. RESULTS: Overall, the SUV(max) in the lung parenchyma correlated with neutrophils and SUV(max) of the mediastinum/hila correlated with the CD4/CD8 ratio. In both groups, a significant, negative correlation between the SUV(max) of the mediastinum/hila and the CD103(+)CD4(+)/CD4(+) ratio was found. In group B, the SUV(max) of the mediastinum/hila correlated with the CD4/CD8 ratio, while the SUV(max) in the lung parenchyma correlated with the CD103(+)CD4(+)/CD4(+) ratio and neutrophils. Significant differences were found in the SUV(max), CD4/CD8 ratio, CD103(+)CD4(+)/CD4(+) ratio and neutrophils between the radiographic stages. The SUV(max) of the lung parenchyma was positively related to the radiographic stage, while the SUV(max) of the mediastinum/hila and CD4/CD8 ratio were inversely related. CONCLUSION: (18)F-FDG PET correlates with the CD4/CD8 ratio and neutrophils, suggesting that (18)F-FDG PET represents this specific cell profile in BAL. High SUV(max) values of the lung parenchyma may therefore correlate with more severe parenchymal involvement, particularly when accompanied by a low SUV(max) of the mediastinum/hila.
PURPOSE: Bronchoalveolar lavage (BAL) and (18)F-fluorodeoxyglucose ((18)F-FDG) PET can both demonstrate sarcoid activity. To assess whether metabolic activity imaged by (18)F-FDG PET represents signs of disease activity as reflected by BAL, (18)F-FDG PET patterns were compared with BAL cell profiles. METHODS: In this retrospective analysis, 77 newly diagnosed pulmonary sarcoidosispatients underwent BAL and (18)F-FDG PET. Based on (18)F-FDG PET, patients were diagnosed with exclusively mediastinal/hilar activity (group A) and activity in the lung parenchyma (group B). Per group, BAL lymphocytes (%), CD4/CD8 ratio, CD103(+)CD4(+)/CD4(+) ratio and neutrophils (%) were compared with the extent of metabolic activity expressed as the maximum standardized uptake value (SUV(max)). Additionally, SUV(max) and BAL parameters per radiographic stage were analysed. RESULTS: Overall, the SUV(max) in the lung parenchyma correlated with neutrophils and SUV(max) of the mediastinum/hila correlated with the CD4/CD8 ratio. In both groups, a significant, negative correlation between the SUV(max) of the mediastinum/hila and the CD103(+)CD4(+)/CD4(+) ratio was found. In group B, the SUV(max) of the mediastinum/hila correlated with the CD4/CD8 ratio, while the SUV(max) in the lung parenchyma correlated with the CD103(+)CD4(+)/CD4(+) ratio and neutrophils. Significant differences were found in the SUV(max), CD4/CD8 ratio, CD103(+)CD4(+)/CD4(+) ratio and neutrophils between the radiographic stages. The SUV(max) of the lung parenchyma was positively related to the radiographic stage, while the SUV(max) of the mediastinum/hila and CD4/CD8 ratio were inversely related. CONCLUSION: (18)F-FDG PET correlates with the CD4/CD8 ratio and neutrophils, suggesting that (18)F-FDG PET represents this specific cell profile in BAL. High SUV(max) values of the lung parenchyma may therefore correlate with more severe parenchymal involvement, particularly when accompanied by a low SUV(max) of the mediastinum/hila.
Authors: Michiel Heron; Walentina A T Slieker; Pieter Zanen; Ellen G van Lochem; Herbert Hooijkaas; Jules M M van den Bosch; Heleen van Velzen-Blad Journal: Clin Immunol Date: 2008-01-08 Impact factor: 3.969
Authors: A Verstraeten; M Demedts; J Verwilghen; A van den Eeckhout; G Mariën; L M Lacquet; J L Ceuppens Journal: Chest Date: 1990-09 Impact factor: 9.410
Authors: Adrian Kruit; Jan C Grutters; Wim B M Gerritsen; Snjezana Kos; Will K W H Wodzig; Jules M M van den Bosch; Henk J T Ruven Journal: Respir Med Date: 2006-08-09 Impact factor: 3.415
Authors: Guy Hagan; Mark Southwood; Carmen Treacy; Robert Mackenzie Ross; Elaine Soon; James Coulson; Karen Sheares; Nicholas Screaton; Joanna Pepke-Zaba; Nicholas W Morrell; James H F Rudd Journal: Pulm Circ Date: 2011 Oct-Dec Impact factor: 3.017
Authors: Andor W J M Glaudemans; Erik F J de Vries; Filippo Galli; Rudi A J O Dierckx; Riemer H J A Slart; Alberto Signore Journal: Clin Dev Immunol Date: 2013-08-21
Authors: Delphine L Chen; Eugene Agapov; Kangyun Wu; Jacquelyn T Engle; Kiran Kumar Solingapuram Sai; Elizabeth Arentson; Katherine J Spayd; Kirby T Moreland; Kelsey Toth; Derek E Byers; Richard A Pierce; Jeffrey J Atkinson; Richard Laforest; Andrew E Gelman; Michael J Holtzman Journal: Mol Imaging Biol Date: 2021-06-16 Impact factor: 3.488